Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TYRO3 | Q06418 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 2/20 | 0.52 |
| ▸ | CASK | O14936 | 2/20 | 0.52 |
| ▸ | MERTK | Q12866 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260652 | 0.76 | TBK1 (0.61) | TBK1 | |
| SCHEMBL16496160 | 0.76 | ALDH1A1 (0.60) | CYP2C19ALDH1A1TSHRNAMPTSMN1; SMN2 | |
| SCHEMBL13897569 | 0.76 | TYRO3 (0.49) | TYRO3CASKTBK1 | |
| SCHEMBL5262926 | 0.75 | GSK3B (0.81) | PTK2 | |
| SCHEMBL4768542 | 0.75 | KMT2A (0.69) | CYP2C19ALDH1A1TSHRNAMPTSMN1; SMN2 | |
| SCHEMBL1735140 | 0.74 | SMN1; SMN2 (0.63) | CYP2C19TYRO3ALDH1A1TSHRNAMPT | |
| SCHEMBL3449465 | 0.74 | STK17A (0.55) | CYP2C19ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14021110 | 0.73 | JAK2 (0.55) | TYRO3ALDH1A1TSHRNAMPTSMN1; SMN2 | |
| SCHEMBL14021562 | 0.73 | JAK2 (0.57) | ALDH1A1TSHRNAMPTSMN1; SMN2TBK1 | |
| SCHEMBL3290772 | 0.73 | CHEK1 (0.58) | TYRO3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | disclosed |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | CYP2C19 688/4885TYRO3 174/4885ALDH1A1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.